Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 25: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Author(s): Stephen Nicholls Added: 1 month ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses… View more

Prevention & Chronic Conditions
ECO 24: Increasing GLP1-RA Efficacy by Targeting Non-coding RNA
Author(s): Riccardo Panella Added: 1 year ago
ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA.Questions1. What is the background of this combinatory approach?2. What data did you present at ERA 24?3. What are the challenges and opportunities in approaching combinatory… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
MicroRNAs for Cardiac Regeneration
Author(s): Camilla Olianti , Mauro Giacca Added: 2 months ago

Heart Failure

Prevention & Chronic Conditions
CardioNerds @AHA23: An Extended Duration Short-Interfering RNA Targeting Lp(a)
Author(s): Steven E Nissen , Maryam Barkhordarian Added: 2 years ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is… View more

Heart Failure

Prevention & Chronic Conditions
ACC.24: Preventing Chemotherapy-Related Heart Damage in Patients with Breast Cancer and Lymphoma: PROACT
Author(s): David Austin Added: 1 year ago
ACC.24 — We are joined onsite by Dr David Austin (South Tees Hospitals NHS Foundation Trust, UK) to discuss the findings from the PROACT trial (NCT03265574).Anthracyclines used in the treatment of breast cancer cause damage to the muscle cells in the heart, resulting in cardiotoxicity.PROACT is a phase III randomised superiority trial of enalapril for the prevention of anthracycline-induced… View more

CV Disease in Special Populations
SK Channels as a New AAD Target
Author(s): Arnela Saljic , Jordi Heijman , Dobromir Dobrev Added: 11 months ago

Electrophysiology & Arrhythmia
Left Atrium Role in Secondary Mitral Regurgitation
Author(s): Markos Koukos , Yannis Dimitroglou , Dimitrios Tsartsalis , et al Added: 1 year ago

Vascular Disease and Surgery

Imaging & Diagnostics
Research Area(s) / Expertise: Job title: Research Director of the Hypertension Unit
ACC 2025: The ALPACA Phase 2 Trial
Author(s): Steven E Nissen Added: 8 months ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,… View more

Prevention & Chronic Conditions
Arterial Hypertension: Highlights from the European Society of Cardiology 2025 Congress
Author(s): Maria Lorenza Muiesan , Matteo Lemoli Added: 1 month ago

Prevention & Chronic Conditions